<h4>Aims</h4>To evaluate the effectiveness of combination therapy with sodium-glucose cotransporter 2 (SGLT-2) inhibitors and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) compared with continued SGLT-2 inhibitor therapy in routine practice among individuals with type 2 diabetes.<h4>Materials and methods</h4>We used nationwide BARMER health claims data and implemented a prevalent new-user design. Here, GLP1R is linked to type 2 diabetes mellitus.